Артериальная тромбоэмболия и острый коронарный синдром у больных со злокачественными новообразованиями. Аналитический обзор. Часть 1

Злокачественные новообразования и противоопухолевая терапия увеличивают риск развития артериальной тромбоэмболии, ишемического инсульта, инфаркта миокарда. Развитие артериальной тромбоэмболии у людей без онкологического анамнеза может быть предвестником еще не выявленных злокачественных новообразований. Понимание процесса артериальной тромбоэмболии является важным условием для правильного ведения пациентов с онкологическими заболеваниями в период лечения и после него с целью профилактики жизнеугрожающих осложнений.

1. Navi B.B., Reiner A.S., Kamel H., Iadecola C., Elkind M.S., Panageas K.S., DeAngelis L.M. OC-02 – Risk of arterial thromboembolism in patients with breast cancer. Thromb. Res., 2016; 140, Suppl 1: S169. doi: 10.1016/S0049-3848(16)30119-0

2. Navi B.B., Reiner A.S., Kamel H., Iadecola C., Okin P.M., Elkind M.S.V., Panageas K.S., DeAngelis L.M. Risk of arterial thromboembolism in patients with cancer. J. Am. Coll. Cardiol., 2017; 70 (8): 926–938. doi: 10.1016/j.jacc.2017.06.047

3. Grilz E., Königsbrügge O., Posch F., Schmidinger M., Pirker R., Lang I.M., Pabinger I., Ay C. Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer. Haematologica, 2018; 103 (9): 1549–1556. doi: 10.3324/haematol.2018.192419

4. Mulder F.I., Horváth-Puhó E., van Es N., Pedersen L., Büller H.R., Bøtker H.E., Sørensen H.T. Arterial thromboembolism in cancer patients: a danish population-based cohort study. JACC CardioOncol., 2021; 3 (2): 205–218. doi: 10.1016/j.jac-cao.2021.02.007

5. Qin Y., Zhang L., Liang X., Sun X., Wang N., Yuan M. Wang Q., Wu D. Venous and arterial thromboembolism in patients with metastatic lung cancer. Clin. Appl. Thromb. Hemost., 2023; 29: 10760296231159121. doi: 10.1177/10760296231159121

6. Cheong M.A., Leader A. Cancer and arterial thrombosis: therapeutic options. Res. Pract. Thromb. Haemost., 2024; 8 (3): 102393. https://doi.org/10.1016/j.rpth.2024.102393

7. Xu Y., Mallity C., Collins E., Siegal D.M., Wang T.F., Carrier M. Anticoagulation for the prevention of arterial thromboembolism in cancer patients by primary tumor site: a systematic review and meta-analysis of randomized trials. Eur. Heart J. Cardiovasc. Pharmacother., 2024; pvae068. doi: 10.1093/ehjcvp/pvae068

8. Zöller B., Ji J., Sundquist J., Sundquist K. Risk of coronary heart disease in patients with cancer: a nationwide follow-up study from Sweden. Eur. J. Cancer, 2012; 48 (1): 121–128. doi: 10.1016/j.ejca.2011.09.015

9. Navi B.B., Reiner A.S., Kamel H., Iadecola C., Okin P.M., Tagawa S.T., Panageas K.S., DeAngelis L.M. Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood, 2019; 133 (8): 781–789. doi: 10.1182/blood-2018-06-860874

10. Starr D.S., Lawrie G.M., Morris G.C. Jr. Unusual presentation of bronchogenic carcinoma: Case report and review of the literature. Cancer, 1981; 47: 398–401. doi: 1002/1097-0142(19810115)47:2<398::aid-cncr2820470230>3.0.co;2-r

11. Khorana A.A., Francis C.W., Culakova E., Fisher R.I., Kuderer N.M., Lyman G.H. Thromboembolism in hospitalized neutropenic cancer patients. J. Clin. Oncol., 2006; 24 (3): 484–490. doi: 10.1200/JCO.2005.03.8877

12. Marković M., Davidović L., Mikić A., Djorić P., Putnik S. Rare forms of peripheral arterial embolism: review of 11 cases. Vascular, 2005; 13: 222–229. doi: 10. 1258/rsmvasc.13.4.222

13. Navi B.B., Singer S., Merkler A.E., Cheng N.T., Stone J.B., Kamel H., Iadecola C., Elkind M.S., DeAngelis L.M. Recurrent thromboembolic events after ischemic stroke in patients with cancer. Neurology, 2014; 83 (1): 26–33. doi: 10.1212/WNL.0000000000000539

14. Khorana A.A., Francis C.W., Culakova E., Kuderer N.M., Lyman G.H. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J. Thromb. Haemost., 2007; 5 (3): 632–634. doi: 10.1111/j.1538-7836.2007.02374.x

15. Gon Y., Morishima T., Kawano T., Okazaki S., Todo K., Sasaki T., Mochizuki H., Miyashiro I. Arterial thromboembolism in Japanese patients with cancer: Incidence, predictors, and survival impact. JACC CardioOncol., 2024; 6 (2): 283–297. doi: 10.1016/j.jaccao.2024.01.006

16. Wang J., Kim Y.D., Kim C.H. Incidence and risk of various types of arterial thromboembolism in patients with cancer. Mayo Clin. Proc., 2021; 96 (3): 592–600. doi: 10.1016/j.mayocp.2020.05.045

17. Bollen E.C., van Duin C.J., van Noord J.A., Janssen J.G., Theunissen P.H. Tumor embolus in lung surgery. A case report and review of the literature. Eur. J. Cardiothorac. Surg., 1993; 7 (2): 104–106. doi: 10.1016/1010-7940(93)90190-m

18. Price L.C., Seckl M.J., Dorfmüller P., Wort S.J. Tumoral pulmonary hypertension. Eur. Respir. Rev., 2019; 28 (151): 180065. doi: 10.1183/16000617.0065-2018

19. Wang F., Gulati R., Lennon R.J., Lewis B.R., Park J., Sandhu G.S., Wright R.S., Lerman A., Herrmann J. Cancer history portends worse acute and long-term noncardiac (but not cardiac) mortality after primary percutaneous coronary intervention for acute st-segment elevation myocardial infarction. Mayo Clin. Proc., 2016; 91 (12): 1680–1692. doi: 10.1016/j.mayocp.2016.06.029

20. Sundbøll J., Veres K., Horváth-Puhу E., Adelborg K., Sørensen H.T. Risk and prognosis of cancer after lower limb arterial thrombosis. Circulation, 2018; 138 (7): 669–677. doi: 10.1161/CIRCULATIONAHA.117.032617

21. Kaschwich M., Peters F., Hischke S., Rieß H.C., Gansel M., Marschall U., L’Hoest H., Heidemann F., Debus E.S., Acar L., Kreutzburg T., Behrendt C.A. Long-term incidence of cancer after index treatment for symptomatic peripheral arterial disease – a health insurance claims data analysis. Vasa, 2020; 49 (6): 493–499. doi: 10.1024/0301-1526/a000901

22. Lee J.M., Yoon C.H. Acute coronary stent thrombosis in cancer patients: a case series report. Korean Circ. J., 2012; 42 (7): 487–491. doi: 10.4070/kcj.2012.42.7.487

23. Ganatra S., Sharma A., Levy M.S. Re-evaluating the safety of drug-eluting stents in cancer patients. JACC Cardiovasc. Interv., 2017; 10 (22): 2334–2337. doi: 10.1016/j.jcin.2017.06.068

24. Yu J., Li A., Laureano M., Crowther M. Frequency of arterial thromboembolism in populations with malignancies: A systematic review. Thromb. Res., 2019; 184: 16–23. doi: 10.1016/j.thromres.2019.10.004

25. Canale M.L., Bisceglia I., Lestuzzi C., Parrini I.; ANMCO Cardio-Oncology Task Force. Arterial thrombosis in cancer: spotlight on the neglected vessels. Anticancer Res., 2019; 39 (9): 4619–4625. doi: 10.21873/anticanres.13642

26. Qi W.X., Shen Z., Tang L.N., Yao Y. Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: an up-to-date meta-analysis. Crit. Rev. Oncol. Hematol., 2014; 92 (2): 71–82. doi: 10.1016/j.critrev-onc.2014.04.004

27. McBane R.D. 2nd. Arterial thrombosis and cancer: implications for screening and risk modification. Mayo Clin. Proc., 2021; 96 (3): 526–528. doi: 10.1016/j.mayocp.2021.01.013

28. Quartermaine C., Ghazi S.M., Yasin A., Awan F.T., Fradley M., Wiczer T., Kalathoor S., Ferdousi M, Krishan S., Habib A., Shaaban A., Kola-Kehinde O., Kittai A.S., Rogers K.A., Grever M., Ruz P., Bhat S., Dickerson T., Byrd J.C., Woyach J., Addison D. Cardiovascular toxicities of BTK Inhibitors in chronic lymphocytic leukemia: JACC: cardiooncology stateof-the-art review. JACC CardioOncol., 2023; 5 (5): 570–590. doi: 10.1016/j.jaccao.2023.09.002

29. Enderoff E., Kirschner P.A. Massive tumor embolism during pulmonary surgery. J. Thorac. Cardiovasc. Surg., 1962; 44: 528–535.

30. Falanga A., Schieppati F., Russo D. Cancer tissue procoagulant mechanisms and the hypercoagulable state of patients with cancer. Semin. Thromb. Hemost., 2015; 41 (7): 756–764. doi: 10.1055/s-0035-1564040

31. Zwicker J.I., Liebman H.A., Neuberg D., Lacroix R., Bauer K.A., Furie B.C., Furie B. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin. Cancer. Res., 2009; 15 (22): 6830–6840. doi: 10.1158/1078-0432.CCR-09-0371

32. Grover S.P., Mackman N. Tissue factor: An essential mediator of hemostasis and trigger of thrombosis. Arterioscler. Thromb. Vasc. Biol., 2018; 38 (4): 709–725. doi: 10.1161/Atvbaha.117.309846

33. Laridan E., Martinod K., de Meyer S.F. Neutrophil extracellular traps in arterial and venous thrombosis. Semin. Thromb. Hemost., 2019; 45 (1): 86–93. doi: 10.1055/s-0038-1677040

34. Moschonas I.C., Tselepis A.D. The pathway of neutrophil extracellular traps towards atherosclerosis and thrombosis. Atherosclerosis, 2019; 288: 9–16. doi: 10.1016/j.atherosclerosis.2019.06.919

35. Massberg S., Grahl L., von Bruehl M.L., Manukyan D., Pfeiler S., Goosmann C., Brinkmann V., Lorenz M., Bidzhekov K., Khandagale A.B., Konrad I., Kennerknecht E., Reges K., Holdenrieder S., Braun S., Reinhardt C., Spannagl M., Preissner K.T., Engelmann B. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat. Med., 2010; 16 (8): 887–896. doi: 10.1038/nm.2184

36. Thеlin C., Demers M., Blomgren B., Wong S.L., von Arbin M., von Heijne A., Laska A.C., Wallén H., Wagner D.D., Aspberg S. NETosis promotes cancer-associated arterial microthrombosis presenting as ischemic stroke with troponin elevation. Thromb. Res., 2016; 139: 56–64. doi: 10.1016/j.thromres.2016.01.009

37. Grover S.P., Hisada Y.M., Kasthuri R.S., Reeves B.N., Mackman N. Cancer therapy-associated thrombosis. Arterioscler. Thromb. Vasc. Biol., 2021; 41 (4): 1291– 1305. doi: 10.1161/ATVBAHA.120.314378

38. Zhu J., Chen Y., Zhang Y., Wang W., Wang Y., Lu Zh., Zhang Yu., Lei H., Li D., Long B., Liu H. Association of immune checkpoint inhibitors therapy with arterial thromboembolic events in cancer patients: A retrospective cohort study. Cancer Med., 2023; 12: 118531–18541. doi: 10.1002/cam4.6455

39. Alexandre J., Salem J.E., Moslehi J., Sassier M., Ropert C., Cautela J., Thuny F., Ederhy S., Cohen A., Damaj G., Vilque J.P., Plane A.F., Legallois D., Champ-Rigot L., Milliez P., Funck-Brentano C., Dolladille C. Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. Eur. Heart J. Cardiovasc. Pharmacother., 2021; 7 (4): 312–320. doi: 10.1093/ehjcvp/pvaa037

40. Salem J.E., Manouchehri A., Bretagne M., Lebrun-Vignes B., Groarke J.D., Johnson D.B., Yang T., Reddy N.M., Funck-Brentano C., Brown J.R., Roden D.M., Moslehi J.J. Cardiovascular toxicities associated with ibrutinib. J. Am. Coll. Cardiol., 2019; 74 (13): 1667–1678. doi: 10.1016/j.jacc.2019.07.056

41. Виценя М.В., Агеев Ф.Т., Гиляров М. Ю., Овчинников А. Г., Орлова Р. В., Полтавская М. Г. Практические рекомендации по коррекции кардиоваскулярной токсичности противоопухолевой лекарственной терапии. Практические рекомендации RUSSCO. Злокачественные опухоли, 2023; 13 (2): 86–111. doi: 10.18027/2224-5057-2023-13-3s2-2-86-111

42. Valent P., Hadzijusufovic E., Schernthaner G.H., Wolf D., Rea D., le Coutre P. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors. Blood, 2015; 125 (6): 901–906. doi: 10.1182/blood-2014-09-594432

43. Paris F., Fuks Z., Kang A., Capodieci P., Juan G., Ehleiter D., Haimovitz-Friedman A., Cordon-Cardo C., Kolesnik R. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science, 2001; 293 (5528): 293–297. doi: 10.1126/science.1060191

44. Texakalidis P., Giannopoulos S., Tsouknidas I., Song S., Rivet D., Reiter E., Reavey-Cantwell J. Prevalence of carotid stenosis following radiotherapy for head and neck cancer: A systematic review and meta-analysis. Head Neck., 2020; 42 (5): 1077–1088. doi: 10.1002/hed.26102

45. Murphy E.S., Xie H., Merchant T.E., Yu J.S., Chao S.T., Suh J.H. Review of cranial radiotherapy-induced vasculopathy. J. Neurooncol., 2015; 122 (3): 421–429. doi: 10.1007/s11060-015-1732-2

46. Feldman S., Gupta D., Navi B.B., Grace Ho K.W., Willeit P., Devlin S., Bolton K.L., Arcila M.E., Mantha S. Tumor genomic profile is associated with arterial thromboembolism risk in patients with solid cancer. JACC CardioOncol., 2023; 5 (2): 246–255. doi: 10.1016/j.jaccao.2023.01.009

47. Buijs J.T., Versteeg H.H. Genes and proteins associated with the risk for cancer-associated thrombosis. Thromb. Res., 2020; 191 Suppl 1: S43–S49. doi: 10.1016/S0049-3848(20)30396-0

48. Al-Samkari H., Leiva O., Dagogo-Jack I., Shaw A., Lennerz J., Iafrate A.J., Bendapudi P.K., Connors J.M. Impact of ALK rearrangement on venous and arterial thrombotic risk in NSCLC. J. Thorac. Oncol., 2020; 15 (9): 1497–1506. doi: 10.1016/j.jtho.2020.04.033

49. Rak J., Milsom C., May L., Klement P., Yu J. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin. Thromb. Hemost., 2006; 32 (1): 54–70. doi: 10.1055/s-2006-933341

50. Vavlukis M., Kotlar I., Chaparoska E., Antova E., Kedev S. Diffuse arterial thrombosis as a first manifestation of occult malignancy. Case Rep. Med., 2016; 2016: 1658392. doi: 10.1155/2016/1658392

51. Selvik H.A., Thomassen L., Bjerkreim A.T., Næss H. Cancer-associated stroke: The Bergen NORSTROKE study. Cerebrovasc. Dis. Extra, 2015; 5 (3): 107–113. doi: 10.1159/000440730

52. Qureshi A.I., Malik A.A., Saeed O., Adil M.M., Rodriguez G.J., Suri M.F. Incident cancer in a cohort of 3,247 cancer diagnosis free ischemic stroke patients. Cerebrovasc. Dis., 2015; 39 (5-6): 262–268. doi: 10.1159/000375154

53. Haugnes H.S., Wethal T., Aass N., Dahl O., Klepp O., Langberg C.W., Wilsgaard T., Bremnes R.M., Fossе S.D. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J. Clin. Oncol., 2010; 28 (30): 4649–4657. doi: 10.1200/JCO.2010.29.9362

54. Ueki Y., Vögeli B., Karagiannis A., Zanchin T., Zanchin C., Rhyner D., Otsuka T., Praz F., Siontis G.C.M, Moro C., Stortecky S., Billinger M., Valgimigli M., Pilgrim T., Windecker S., Suter T., Räber L. Ischemia and bleeding in cancer patients undergoing percutaneous coronary intervention. JACC CardioOncol., 2019; 1 (2): 145–155. doi: 10.1016/j.jaccao.2019.11.001

55. Potts J.E., Iliescu C.A., Lopez Mattei J.C., Martinez S.C., Holmvang L., Ludman P., de Belder M.A., Kwok C.S., Rashid M., Fischman D.L., Mamas M.A. Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States. Eur. Heart J., 2019; 40 (22): 1790–1800. doi: 10.1093/eurheartj/ehy769

56. Lyon A.R., Lуpez-Fernández T., Couch L.S., Asteggiano R., Aznar M.C., Bergler-Klein J., Boriani G., Cardinale D., Cordoba R., Cosyns B., Cutter D.J., de Azambuja E., de Boer R.A., Dent S.F., Farmakis D., Gevaert S.A., Gorog D.A., Herrmann J., Lenihan D., Moslehi J., Moura B., Salinger S.S., Stephens R., Suter T.M., Szmit S., Tamargo J., Thavendiranathan P., Tocchetti C.G., van der Meer P., van der Pal H.J.H. ESC Scientific Document Group. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur. Heart J., 2022; 43 (41): 4229–4361. doi: 10.1093/eurheartj/ehac244

57. Gross C.M., Posch M.G., Geier C., Olthoff H., Krämer J., Dechend R., Dietz R., Ozcelik C. Subacute coronary stent thrombosis in cancer patients. J. Am. Coll. Cardiol., 2008; 51 (12): 1232–1233. doi: 10.1016/j.jacc.2007.11.061

58. Bianco M., D’ascenzo F., Raposeiras Roubin S., Kinnaird T., Peyracchia M., Ariza-Solé A., Cerrato E., Manzano-Fernández S., Gravinese C., Templin C., Destefanis P., Velicki L., Luciano A., Xanthopoulou I., Rinaldi M., Rognoni A., Varbella F., Boccuzzi G., Omedè P., Montabone A., Bernardi A., Taha S., Rossini R., Durante A., Gili S., Magnani G., Autelli M., Grosso A., Blanco P.F., Giustetto C., Garay A. Quadri G., Queija B.C., Srdanovic I., Paz R.C., Fernández M.C., Pousa I.M., Gallo D., Morbiducci U., Dominguez-Rodriguez A., Lopez-Cuenca Á., Cequier A., Alexopoulos D., Iсiguez-Romo A., Pozzi R., Assi E.A., Valgimigli M. Comparative external validation of the PRECISEDAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor. Int. J. Cardiol., 2020; 301: 200–206. doi: 10.1016/j.ijcard.2019.11.132

59. Bharadwaj A., Potts J., Mohamed M.O., Parwani P., Swamy P., Lopez-Mattei J.C., Rashid M., Kwok C.S., Fischman D.L., Vassiliou V.S., Freeman Ph., Michos E.D., Mamas M.A. Acute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USA. Eur. Heart J., 2020; 41 (23): 2183–2193. doi: 10.1093/eurheartj/ehz851

60. Duarte C.W., Lindner V., Francis S.A., Schoormans D. Visualization of cancer and cardiovascular disease co-occurrence with network methods. JCO Clin. Cancer Inform., 2017; 1: 1–12. doi: 10.1200/CCI.16.00071

61. Milazzo V., Cosentino N., Campodonico J., Lucci C., Cardinale D., Cipolla C.M., Marenzi G. Characteristics, management, and outcomes of acute coronary syndrome patients with cancer. J. Clin. Med., 2020; 9 (11): 3642. doi: 10.3390/jcm9113642

62. Ederhy S., Cohen A., Boccara F., Puymirat E., Aissaoui N., Elbaz M., Bonnefoy-Cudraz E., Druelles P., Andrieu S., Angoulvant D., Furber A., Ferrières J., Schiele F., Cottin Y., Simon T., Danchin N. FASTMI investigators. In-hospital outcomes and 5-year mortality following an acute myocardial infarction in patients with a history of cancer: Results from the French registry on Acute ST-elevation or non-ST-elevation myocardial infarction (FAST-MI) 2005 cohort. Arch. Cardiovasc. Dis., 2019; 112 (11): 657–669. doi: 10.1016/j.acvd.2019.06.012

63. Gevaert S.A., Halvorsen S., Sinnaeve P.R., Sambola A., Gulati G., Lancellotti P., van der Meer P., Lyon A.R., Farmakis D., Lee G., Boriani G., Wechalekar A., Okines A., Asteggiano R. Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology-Part 1: acute coronary syndromes and acute pericardial diseases. Eur. Heart J. Acute Cardiovasc. Care, 2021; 10 (8): 947–959. doi: 10.1093/ehjacc/zuab056

64. Pushparaji B., Donisan T., Balanescu D.V., Park J.K., Monlezun D.J., Ali A., Inanc I.H., Caballero J., Cilingiroglu M., Marmagkiolis K., Iliescu C. Coronary revascularization in patients with cancer. Curr. Treat. Options. Cardiovasc. Med., 2023; 25 (6): 143–158. doi: 10.1007/s11936-023-00982-9

65. Yusuf S.W., Daraban N., Abbasi N., Lei X., Durand J.B., Daher I.N. Treatment and outcomes of acute coronary syndrome in the cancer population. Clin. Cardiol., 2012; 35 (7): 443–450. doi: 10.1002/clc.22007

66. Pothineni N.V., Shah N.N., Rochlani Y., Saad M., Kovelamudi S., Marmagkiolis K., Bhatti S., Cilingiroglu M., Aronow W.S., Hakeem A. Temporal trends and outcomes of acute myocardial infarction in patients with cancer. Ann. Transl. Med., 2017; 5 (24): 482. doi: 10.21037/atm.2017.11.29

67. Roule V., Verdier L., Blanchart K., Ardouin P., Lemaitre A., Bignon M., Sabatier R., Alexandre J., Beygui F. Systematic review and meta-analysis of the prognostic impact of cancer among patients with acute coronary syndrome and/or percutaneous coronary intervention. BMC Cardiovasc. Disord., 2020; 20 (1): 38. doi: 10.1186/s12872-020-01352-0

68. Iliescu C.A., Grines C.L., Herrmann J., Yang E.H., Cilingiroglu M., Charitakis K., Hakeem A., Toutouzas K.P., Leesar M.A., Marmagkiolis K. SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the cardiological society of india, and sociedad Latino Americana de Cardiologıa intervencionista). Catheter Cardiovasc. Interv., 2016; 87 (5): E202–223. doi: 10.1002/ccd.26379